OncoTartis Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 3

OncoTartis General Information

Description

Developer of anti-cancer drugs designed to help patients recover from acute leukemia. The company's drug development approach is designed to develop small molecules for the treatment of malignancies originating from specific tissues that are either non-essential for the general viability of mammalian organisms or can be effectively replaced, enabling patients to have access to novel therapies for the treatment of cancer and white cell diseases.

Contact Information

Website
oncotartis.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 640 Ellicott Street
  • Suite 480
  • Buffalo, NY 14203
  • United States
+1 (716) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoTartis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 000.00 Completed Clinical Trials - Phase 1
5. Later Stage VC 11-Dec-2017 000 000.00 Completed Clinical Trials - Phase 1
4. Grant 07-Jun-2017 000.00 00.000 Completed Generating Revenue
3. Grant 00.000 Completed Generating Revenue
2. Later Stage VC (Series B) 01-Jul-2016 $1.85M $8.25M Completed Generating Revenue
1. Early Stage VC (Series A) 17-Feb-2011 $6.4M $6.4M Completed Generating Revenue
To view OncoTartis’s complete valuation and funding history, request access »

OncoTartis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of anti-cancer drugs designed to help patients recover from acute leukemia. The company's drug development app
Drug Discovery
Buffalo, NY
000.00
000000 - 000 000.00

000000

trud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis
0000000000000
Gaithersburg, MD
00 As of 0000
00000
00000000 00000

00000

bore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000000000000
Geneva, Switzerland
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoTartis Competitors (49)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Light Chain Bioscience Private Equity-Backed Geneva, Switzerland 00 00000 00000000000 00000
Kite Pharma Formerly VC-backed Santa Monica, CA 0000 00000 000000&0 00000
Viriom Venture Capital-Backed San Diego, CA 0 000.00 0000000000 0 000.00
NuvOx Pharma Venture Capital-Backed Tucson, AZ 00 000.00 00000000000 000.00
You’re viewing 5 of 49 competitors. Get the full list »

OncoTartis Patents

OncoTartis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10208032-B2 Benzamide and nicotinamide compounds and methods of using same Active 24-Dec-2013 0000000000 00
AU-2014369926-A1 Benzamide and nicotinamide compounds and methods of using same Active 24-Dec-2013 0000000000
US-20190031658-A1 Benzamide and nicotinamide compounds and methods of using same Active 24-Dec-2013 0000000000 0
US-10538520-B2 Benzamide and nicotinamide compounds and methods of using same Inactive 24-Dec-2013 0000000000 00
US-20160347748-A1 Benzamide and nicotinamide compounds and methods of using same Active 24-Dec-2013 C07D471/04 0
To view OncoTartis’s complete patent history, request access »

OncoTartis Executive Team (6)

Name Title Board Seat Contact Info
Andrei Gudkov Ph.D Co-Founder & Chief Scientific Officer
Aleksandra Kotlyarova Director of Operations
Olga Chernova Ph.D Co-Founder & Vice President of Research & Development
Alexander Polinsky Ph.D Co-Founder & Chief Executive Officer
Eric Rowinsky MD Chief Medical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

OncoTartis Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Pharmstandard Corporation Minority 000 0000 000000 0
Startup Village Government 000 0000 000000 0
Skolkovo Foundation Limited Partner 000 0000 000000 0
To view OncoTartis’s complete investors history, request access »

OncoTartis FAQs

  • When was OncoTartis founded?

    OncoTartis was founded in 2011.

  • Who is the founder of OncoTartis?

    Andrei Gudkov Ph.D, Leonov Aleksandrovich, Olga Chernova Ph.D, and Alexander Polinsky Ph.D are the founders of OncoTartis.

  • Who is the CEO of OncoTartis?

    Alexander Polinsky Ph.D is the CEO of OncoTartis.

  • Where is OncoTartis headquartered?

    OncoTartis is headquartered in Buffalo, NY.

  • What industry is OncoTartis in?

    OncoTartis’s primary industry is Drug Discovery.

  • Is OncoTartis a private or public company?

    OncoTartis is a Private company.

  • What is OncoTartis’s current revenue?

    The current revenue for OncoTartis is 000000.

  • How much funding has OncoTartis raised over time?

    OncoTartis has raised $14.2M.

  • Who are OncoTartis’s investors?

    Pharmstandard, Startup Village, and Skolkovo Foundation have invested in OncoTartis.

  • Who are OncoTartis’s competitors?

    NexImmune, Light Chain Bioscience, Kite Pharma, Viriom, and NuvOx Pharma are some of the 49 competitors of OncoTartis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »